Vesiculab的动态

查看Vesiculab的组织主页
Vesiculab

10,909 位关注者

Producing engineered extracellular vesicles for therapeutics applications: in this study, Kristin Luther, Joe Nabhan at Vesigen Therapeutics, Inc. and collaborators evaluated two scalable strategies for generating GFP-loaded ARMM-engineered EVs: transient transfection and stable cell line-based production. The upstream ARMM production processes used a suspension HEK293-derived line called 5B8 from Lonza, with production assessed in both shake flasks and bioreactors. For downstream ARMM purification, they employed Tangential Flow Filtration and Anion Exchange Chromatography https://lnkd.in/eWs8TfSM In vivo, ARMMs demonstrated rapid biodistribution, primarily to the spleen and liver, with lesser distribution to the kidneys and lungs. The successful scale-up of ARMM production highlights the potential of engineered EVs. An article also authored by Ali Navaei, Leah Gens, Carson Semple, Pearl Moharil, Ilaria Passalacqua, Komal Vyas, Qiyu Wang, Shu-Lin Liu, Lucy Sun, Senthil Ramaswamy and Davide Zocco #extracellularvesicles #exosomes #bioengineering #translationalmedicine #cellculture #Vesiculab

  • Characterization of ARMMs purified by ultracentrifugation. (A) Particle concentration was determined by NTA, and the mass balance of particles before and after ultracentrifugation was calculated. (B–C) The size distributions for particles in the CM and resuspended pellet were also determined by NTA, and the median size was labeled. (D) Western blot for ARRDC1 and the EV marker protein Syntenin in the CM and UC pellet at 4.5 × 108 particles/lane. (E) Western blot for CD63 and CD9 in the CM and UC pellet at 4.5 × 108 particles/lane.

要查看或添加评论，请登录

最相关的动态

Vesiculab

10,909 位关注者